Daiichi Sankyo’s Breakthrough Enhertu Delivery Boosts Stock Prices
Daiichi Sankyo has announced a notable change in the delivery method for its flagship cancer drug, Enhertu. Shifting from intravenous to subcutaneous injections is expected to ease the burden on patients significantly, leading to a substantial rise in the company’s stock price. This strategic move not only enhances patient care but also strengthens Daiichi Sankyo’s position in the pharmaceutical market, with the company’s stock (4568.T) seeing a noteworthy 5.68% increase to ¥3,997.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
